Login / Signup

Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma.

Melania CarlisiR Lo PrestiFederica PlanoSalvatrice MancusoSergio SiragusaGregorio Caimi
Published in: Scientific reports (2024)
RDW is an erythrocyte index that increase in multiple myeloma, in which it appears to have an important role in predicting outcome. For this reason, we performed a retrospective analysis to evaluate the relationships of RDW with some important prognostic predictors. Specifically, in a cohort of 190 newly diagnosed multiple myeloma patients, we have examined the behaviour of RDW and its trend in relation to the ISS stage and other prognostic factors, such as albumin, beta-2 microglobulin, LDH and bone marrow plasma cell infiltration. We performed the analysis in the entire cohort of patients and in the three different disease isotypes (Light chain, IgA, and IgG multiple myeloma). The evaluation of RDW in the different isotypes was made with the Kruskal-Wallis test, integrated by the Dunn test. The comparison between the subgroups allocated above and below the median value of each prognostic factor, was made with the Mann-Whitney test. From our analysis, we observed that RDW is higher in the IgA multiple myeloma, and it increases significantly from ISS I to III. Moreover, RDW increases in the presence of lower albumin values, higher levels of beta2-microglobulin and LDH and in the presence of a greater bone marrow plasma cell infiltrate.
Keyphrases
  • prognostic factors
  • multiple myeloma
  • newly diagnosed
  • bone marrow
  • end stage renal disease
  • ejection fraction
  • mesenchymal stem cells
  • single cell
  • cell therapy
  • data analysis